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ABSTRACT 
OBJECTIVE: To systematically compare the efficacy, predictability, safety, 
post-operative haze, pain scores and epithelial healing time of four corneal surface 
ablation procedures (PRK, T-PRK, LASEK and Epi-LASIK) and to provide 
evidence-based rankings of these treatments. 
DESIGN: Systematic review and network meta-analysis. 
DATA SOURCES: PubMed, Embase, The Cochrane Library and the US trial registry 
(until September 2016).  
ELIGIBILITY CRITERIA: Databases were searched without language restrictions 
for randomized controlled trials of comparisons between two or more of the included 
procedures. Studies using mitomycin C (MMC) during surgery or with less than 3 
months of follow-up after randomization were excluded. 
OUTCOME MEASURES: The primary outcomes in this study were efficacy, 
predictability and safety. Haze, pain scores and epithelial healing time were analyzed 
as secondary outcomes. 
RESULTS: A total of 18 studies involving 1423 eyes were included. There were no 
statistically significant differences in efficacy, predictability, safety, haze, pain scores 
on day 1 and epithelial healing time between any pair of treatments analyzed. 
Epi-LASIK had statistically significantly higher pain scores on day 3 when compared 
with PRK (weighted mean differences [WMD] 2.17, 95% credible intervals [CrI] 
0.19-4.01) and T-PRK (WMD 2.69, 95% CrI 0.51-4.84). The SUCRA (Surface under 
the Cumulative RAnking curve) ranking results (from best to worst) showed that 
LASEK ranked highest in terms of efficacy, predictability, safety and pain scores on 
day 1 (SUCRA values were 75.0%, 72.0%, 44.3% and 26.0% respectively). 
Epi-LASIK ranked best for haze scores at grade 1 (SUCRA values 30.3% and 21.7% 
respectively). T-PRK ranked best for haze scores at grade 0.5 or higher, pain scores on 
day 3 and epithelial healing time (SUCRA values are 19.3%, 6.3%, 3.3% 
respectively). 
CONCLUSIONS: This network meta-analysis demonstrates that all the surface laser 
refractive surgeries are comparable in terms of efficacy, predictability, safety, 
post-operative haze and comfort with the exception of pain scores on day 3. 
Epi-LASIK was significantly more painful when compared with PRK and T-PRK 
on post-operative day 3.
INTRODUCTION 
Uncorrected refractive error, particularly myopia, is the leading cause of visual 
impairment throughout the world.1-3 Laser corneal refractive surgery is an effective 
alternative to optical correction of refractive errors with glasses or contact lenses, 
particularly for myopia. A range of surgical techniques have been developed that 
change refraction by reshaping the cornea through the photoablative removal of 
corneal tissue. Photorefractive keratectomy (PRK) was the first corneal refractive 
surgical technique using the excimer laser and was introduced more than 25 years 
ago.4, 5  
During the intervening years, traditional PRK declined in popularity with the 
introduction of intra-stromal ablative techniques such as LASIK,6, 7 which addressed 
the principle limitations of PRK: post-operative pain, delayed epithelial healing, and 
post-operative stromal haze. PRK does, however, retain certain advantages over 
LASIK such as inflicting less corneal biomechanical insult and avoiding both 
intraoperative and late flap-related complications.8 Several other surface ablation 
procedures have been developed, all of which can be considered derivations of PRK, 
most notably transepithelial photo-refractive keratectomy (T-PRK), laser epithelial 
keratomileusis (LASEK)9 and epipolis laser in situ keratomileusis (Epi-LASIK).10, 11 
These alternative surface ablation approaches have evolved to avoid the shortcomings 
of PRK while retaining its biomechanical advantages.12, 13  
A key component of the surface ablative techniques is the method of epithelial 
removal. Alcohol or mechanical debridement may be used or the preservation of the 
epithelium as a flap. Another alternative is T-PRK, where epithelial removal is 
performed using laser phototherapeutic (PTK) ablation followed by a stromal laser 
refractive ablation. This has several advantages, including no instrument contact with 
the cornea, reduced intervention time, and the potential to minimize the size of an 
epithelial defect required for stromal ablation, as well as the avoidance of alcohol and, 
thus, potential toxicity.14 Although these new technologies have offered apparent 
improvements over traditional PRK with alcohol, they each have different advantages 
and disadvantages. What is currently lacking is a comprehensive evidence based 
approached to determine the relative merits of each procedure. 
The speed with which refractive surgery techniques have evolved has created several 
challenges, in particular, the evidence comparing specific procedures is often lacking. 
Several conventional pair wise meta-analyses of four refractive surgery techniques 
above have been published,15-18 but these publications share several limitations. Firstly, 
they are unable to provide clear hierarchies for all available treatments due to a lack 
of head to head comparisons. Secondly, some previous analyses included some 
non-randomized controlled trials that might influence the quality of evidence. A 
network meta-analysis can combine direct evidence from individual trials and indirect 
evidence gleaned using statistical techniques across trials, enabling simultaneous 
“all-way” comparisons of multiple interventions.19 This technique is therefore 
particularly suitable to address questions relating to the relative safety and benefits of 
different corneal surface ablation techniques. We performed this network 
meta-analysis of available randomized controlled trials (RCTs) to systematically 
compare the efficacy, predictability, safety and post-operative haze, pain scores and 
epithelial healing time of the four major forms of surface ablative procedures and to 
provide evidence-based rankings of these treatments. 
 
METHODS 
This systematic review complies with the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) network meta-analysis extension 
statement.20 
Outcome Measurements  
Efficacy (uncorrected visual acuity (UCVA) of 20/20 or better), predictability 
(refractive spherical equivalent [SE] within ±0.50 D of the target) and safety (losing 
two or more lines of best spectacle corrected visual acuity [BSCVA]) were set as 
primary outcome measures. Haze, pain scores and epithelial healing time were set as 
secondary outcome measures. Pain data was assessed using a 10-point scale at day 1 
and day 3 post-operatively. When data at day 3 were not available, the outcome at the 
follow-up time point closest to day 3, such as day 2 or day 4 was used. The results of 
efficacy, predictability, safety and haze were analyzed at 6 months post-operatively. 
When data at 6 months were not available, the outcome at the follow-up time point 
closest to 6 months was used. 
Eligibility Criteria 
Trials were included if they met the following criteria: (1) treated population: patients 
with myopia; (2) interventions: PRK, T-PRK, LASEK, Epi-LASIK (see Table 1 for 
the full name of these surgical abbreviations); (3) comparisons: two or more laser 
corneal surface ablation techniques (as listed above); (4) at least one of the following 
outcomes: efficacy, safety, predictability, post-operative haze, pain and epithelial 
healing time; and (5) study design: randomized controlled trial. We excluded trials if 
they contained only one or none of the surface ablation techniques, did not use 
randomization for treatment allocation, used mitomycin C (MMC) during surgery or 
if participants were followed up for less than 3 months after surgery.. 
Search Methods 
A systematic literature review was conducted using PubMed, Embase, The Cochrane 
Library and the US trial registry (www.ClinicalTrial.gov) for RCTs published up to 
September 2016 without language restrictions. The full search strategies are shown in 
appendix 1. We also manually examined the reference lists of clinical trials, related 
meta-analyses and systematic reviews to identify relevant studies. 
Study Selection 
Screening was performed by two independent investigators (YYH, BHS). They 
retrieved the full-text articles that appeared relevant after reviewing the titles and 
abstracts. They independently assessed full-text articles for final eligibility. Any 
discrepancies were resolved by focused discussion or consultation with an additional 
investigator (RXT). 
Data Extraction and Risk of Bias Assessment 
Two investigators independently extracted information into an electronic database, 
including the participant and intervention characteristics, outcomes, and quantitative 
results for treatment effects. For data that were missing or could not be directly 
obtained, we contacted the authors of trial reports or used GetData GraphDigitizer 
2.24 (http://getdata-graph-digitizer.com) to read data from figures. To appraise the 
study quality, the Cochrane Collaboration risk-of-bias method was used.21 In this 
method, we graded all reports at low, high, or unclear risk of bias for each of the 
following items: random sequence generation and allocation concealment (both items 
relate to selection bias), blinding of participants and personnel (detection bias), 
incomplete outcome data (attrition bias), selective reporting (reporting bias) and other 
biases. 
Data Analysis 
We first conducted traditional pairwise meta-analyses for direct comparisons using 
random-effects models. For binary outcomes, relative effect sizes were calculated as 
odds ratios (OR) with 95% confidence intervals (CI). For continuous outcomes, 
relative effect sizes were calculated as weighted mean differences (WMD) with 95% 
CI. For positive outcomes (i.e. efficacy and predictability where a greater value 
indicates a better result), OR >1 or WMD >0 correspond to beneficial treatment 
effects of the first treatment compared with the second treatment. When the outcomes 
are negative (i.e. safety, haze, pain, epithelial healing time, where a greater value 
indicates a worse result), OR <1 or WMD <0 correspond to beneficial treatment 
effects of the first treatment compared with the second treatment. We used visual 
inspection of the forest plots and the I2 statistic22 (values of 50% or more indicate 
substantial heterogeneity) to investigate the possibility of statistical heterogeneity. We 
used STATA version 12.0 (StataCorp LP, College Station, TX) for statistical analyses.  
To incorporate indirect comparisons, we performed Bayesian random-effects network 
meta-analyses using Markov chain Monte Carlo methods in GeMTC GUI 0.14.323 to 
estimate pooled ORs and WMD with 95% credible intervals (CrI). We used four 
parallel chains and obtained 50000 samples after a 20000-sample burn-in in each 
chain. To check convergence, we used the Gelman and Rubin diagnostic24 and trace 
plots. We ranked treatments based on the analysis of ranking probabilities and the 
Surface Under the Cumulative RAnking curve (SUCRA)25. The SUCRA values, 
expressed as a percentage, show the relative probability of an intervention being the 
best option. Inconsistency between direct and indirect evidence was assessed by a 
"node-splitting" approach.26 Further sensitivity analyses were undertaken by removal 
of trials that caused high heterogeneity in direct comparisons or appeared to introduce 




Figure 1 shows the detailed steps of the study selection process. The literature search 
yielded 514 potentially relevant studies (detailed search strategy is shown in 
Appendix I). Of these, 33 potentially eligible studies were retrieved from the 
electronic databases and 4 additional studies were located from the references of 
selected studies, making a total of 37. After excluding 19 studies on the basis of the 
pre-defined inclusion criteria, 18 studies were included in the network meta-analysis. 
Study Characteristics and Network Geometry 
A summary of all eligible studies is shown in Appendix 2. Included trials were 
published between 2001 and 2015. A total of 1423 eyes which underwent one of the 
four different interventions were evaluated; 618 eyes were in the PRK group, 616 
eyes in the LASEK group, 117 eyes in the Epi-LASIK group, and 72 eyes in the 
T-PRK group (Figure 2). Almost all trials had two treatment arms with the exception 
of O'Doherty 200727 which had three treatment arms. Of the included 18 trials, 5 
(27.8%) recruited participants from Europe, 7 (38.9%) recruited participants from 
Asia, 4 (22.2%) recruited participants from North America, and 2 (11.1%) recruited 
participants from Latin America (all from Brazil).  
Quality of Trials 
The quality of the studies included in the Network Meta-Analysis (NMA) is shown in 
Appendix 3. In relation to the complete outcome data, almost one quarter of trials 
were rated as “high risk of bias” (4 trials, 22.2%), but the majority of trials were rated 
at “low risk of bias”, because they reported the masking of participants and personnel 
(10 trials, 55.6%), used appropriate randomization techniques (10, 55.6%) and did not 
selectively report outcomes (11 trials, 61.1%). Those rated as “unclear risk of bias” 
were trials that reported allocation concealment and masking of outcome assessment 
(14 and 12, respectively). 
Results of meta-analysis 
Direct comparisons 
Table 2 shows the results of efficacy, predictability and safety based on direct 
comparisons. Twelve articles reported the percentage of eyes with UCVA of 20/20 or 
better post-operatively (defined as efficacy). The results show that there was no 
statistically significant difference as well as high heterogeneity for all comparisons. 
Predictability was measured by the proportion of eyes where the post-operative 
refractive error was within ±0.5 D of the target refraction. We found that 10 studies 
had sufficient data for this analysis. Statistical analyses of these data found no 
statistically significant effect. The proportion of eyes losing 2 or more lines of BSCVA 
was used as a measure of safety. This parameter was reported in 7 studies. The results 
show that there was no statistically significant difference as well as high heterogeneity 
for all comparisons. 
Similarly, Tables 3 and 4 show the results of post-operative haze, pain scores and 
epithelial healing time based on direct comparisons. Six trials reported haze scores. 
We found one statistically significant difference between LASEK vs PRK (WMD 
-0.19, 95% CI -0.37 to -0.01), while high heterogeneity was observed between 
LASEK vs PRK with I2 = 88.9% (forest plots in Appendix IV). We also analyzed the 
data at two different grades (grade 0.5 or higher and grade 1.0 or higher) in 7 trials, 
for both grades, no statistically significant difference was found and high 
heterogeneity was found. 
Six studies reported post-operative pain scores. We analyzed the post-operative pain 
scores at day 1 and day 3. Statistically significant differences were found between 
PRK vs T-PRK at day 1 (WMD 1.24, 95% CI 1.00 to 1.48), LASEK vs T-PRK at day 
1 (WMD -1.23, 95% CI -2.10 to -0.36), PRK vs Epi-LASIK at day 3 (WMD -2.16, 
95% CI -3.55 to -0.77), and PRK vs T-PRK at day 3 (WMD -0.48, 95% CI -0.23 to 
-0.73). There was no high heterogeneity for all comparisons. 
Fourteen studies reported epithelial healing time. A statistically significant difference 
was found between PRK and T-PRK (WMD 1.57, 95% CI 1.33 to 1.75). We also 
found high heterogeneity between PRK vs Epi-LASIK (I2 = 91.4%), PRK vs LASEK 
(I2 = 97.1%), LASEK vs Epi-LASIK (I2 = 76.6%) (forest plots in Appendix 4). 
Combination of direct and indirect comparisons 
Figure 3 shows the results of efficacy, predictability and safety based on Bayesian 
network meta-analyses that combines direct and indirect comparisons. The ranking 
probabilities for all procedures are presented in Appendix 5, along with the ranking 
probabilities of other results. For the primary outcomes, there were no statistically 
significant difference in efficacy, safety and predictability. As for the ranking results, 
the efficacy ordered from the best to worst on the SUCRA values (Figure 6) were as 
follows: LASEK (75.0%), PRK (50.7%), Epi-LASIK (38.0%), T-PRK (36.0%). The 
predictability ordered from the best to worst on the SUCRA values (Figure 7) were as 
follows: LASEK (72.0%), Epi-LASIK (44.0%), PRK (34.0%). The safety ordered 
from the best to worst (safe to unsafe) on the SUCRA values (Figure 8) were as 
follows: LASEK (44.3%), Epi-LASIK (47.0%), T-PRK (50.3%), PRK (58.7%). 
The results for post-operative haze based on Bayesian network meta-analyses is 
shown in Figure 4. There was no statistically significant difference between any of 
the studied techniques. The haze scores were ranked from the best (least haze) to 
worst (most haze) depending on the SUCRA values (Figure 9) as follows: 
Epi-LASIK (30.3%), LASEK (39.7%), T-PRK (46.3%), PRK (84.7%). The haze 
scores at grade 0.5 or higher, were ranked from best to worst (Figure 10) as follows: 
T-PRK (19.3%), Epi-LASIK (38.0%), PRK (66.0%), LASEK (76.7%). The haze 
scores at grade 1.0 or higher, were ranked from best to worst (Figure 11) as follows: 
Epi-LASIK (21.7%), T-PRK (27.7%), PRK (67.7%), LASEK (82.3%). 
The results for pain scores and epithelial healing time can be seen in Figure 5. As 
shown, there are statistically significant differences when Epi-LASIK is compared 
with PRK (WMD 2.17, 95% CrI 0.19-4.01) and T-PRK (WMD 2.69, 95% CrI 
0.51-4.84) in terms of pain scores on day 3. For pain on the first day, the rank from 
best result to worst (Figure 12) is as follows: LASEK (26.0%), T-PRK (40.0%), 
Epi-LASIK (62.3%), PRK (71.0%). For pain on the third day, the rank from best 
result to worst (Figure 13) is: T-PRK (6.3%), PRK (43.3%), LASEK (53.3%), 
Epi-LASIK (97.7%). The rank of the epithelial healing time from best to worst 
(Figure 14) is: T-PRK (3.3%), LASEK (62.3%), PRK (63.7%), Epi-LASIK (71.3%), 
more closely matching the rank for pain on day 3, than pain on day 1. 
Inconsistency 
Node-splitting analysis between LASEK, PRK and T-PRK for close-loop comparisons 
in terms of pain score on day 1 shows significant inconsistency (p=0.05). However, 
for other results comparisons between direct and indirect estimates did not suggest 
significant inconsistency between direct and indirect evidence (Appendix 6, p-value 
varying from 0.22 to 0.99).  
Sensitivity Analysis 
As mentioned above, we found some high heterogeneity and inconsistency for certain 
comparisons, so we performed a sensitivity analysis by removing trials that 
contributed the highest heterogeneity in direct comparisons or introduced statistical 
inconsistency in network meta-analyses. For the post-operative haze scores in direct 
comparison of PRK vs LASEK, Autrata (2003)28 was removed as it was identified as 
the main source of heterogeneity. This changed the rank and SUCRA values as 
follows: Epi-LASIK (17.7%), LASEK (43.7%), T-PRK (50.7%), PRK (88.3%). When 
Wang 201429 (LASEK vs T-PRK for post-operative pain scores on day 1) was 
removed from the analysis of pain scores at day 1 (on account of contributing 
significant inconsistency in close-loop comparisons), the rank and SUCRA value 
changed to T-PRK (7.7%), LASEK (54.3%), Epi-LASIK (66.3%), PRK (71.7%). 
For direct comparisons, high heterogeneity is apparent for epithelial healing time. 
This heterogeneity remains even after removing the two largest contributors, which 
prevents any meaningful sensitivity analysis for this outcome. This variability also 
points to the need for cautious interpretation of the data on epithelial healing time. 
 
DISCUSSION 
This study provides an in-depth statistical comparison of the major laser corneal 
surface ablation refractive procedures for correcting myopia, combining data from 18 
trials and 1423 eyes. It also considers a wide range of clinically relevant outcomes 
including post-operative pain, haze and epithelial healing time. The variety of 
available surface ablation techniques and the lack of large definitive trials with 
multiple treatment arms make a network meta-analysis particularly useful in this field.  
The main conclusion of this analysis is the confirmation30 that all the surface laser 
refractive technologies included in this analysis have excellent efficacy, predictability 
and safety, at least in the short term. For many of the outcomes analyzed no 
statistically significant differences were found, i.e. in relation to efficacy, 
predictability, safety, post-operative haze, pain score on day 1 and epithelial healing 
time. However, in terms of pain score on day 3, Epi-LASIK was significantly more 
painful when compared with PRK and T-PRK.  
As well as determining the statistical differences of specific outcomes between 
procedures, our analysis (using SUCRA) provides a numerical ranking of all the 
procedures for each outcome (as shown in Figures 6-14). LASEK demonstrates 
relative advantages in three visual outcomes (efficacy, predictability and safety) 
compared with the other techniques assessed, but results in greater post-operative 
corneal haze. Epi-LASIK demonstrates better haze scores while performing less well 
in relation to post-operative comfort (pain score and epithelial healing time). T-PRK 
tops the rankings in relation to post-operative haze grade 0.5 or higher, pain scores 
and epithelial healing time. Notably, traditional PRK fails to achieve top ranking in 
any of the studied outcomes. The SUCRA values showed the relative probability of an 
intervention being the best option. This provides an estimate of the relative 
dominance of the treatment in the absence of significant differences in statistical 
analysis. 
Efficacy, predictability and safety are perhaps the most important outcomes in 
evaluations of corneal refractive surgery.31, 32 There are several trials and 
meta-analyses that compare the direct evidence for these three outcomes between 
different surface laser procedures. In 2010, Zhao et al.15 performed a meta-analysis to 
examine possible differences in efficacy and predictability between LASEK and PRK. 
They indicated that LASEK had no significant benefits over PRK in terms of efficacy 
(OR 0.86, 95% CI 0.61-1.20) or predictability (OR 0.90, 95% CI 0.63-1.29). Wu et 
al.16 compared Epi-LASIK and PRK in relation to efficacy and predictability, 
reporting no statistically significant differences in either efficacy (RR 1.43, 95% CI 
0.85-2.40) or predictability (RR 1.03, 95% CI 0.92-1.16). These findings are similar 
to our research results, but we also found no statistical significant difference in safety 
when PRK is compared with either Epi-LASIK or LASEK. Furthermore, we found 
that LASEK demonstrates relative advantages in these three outcomes in terms of 
ranking and that PRK ranks lowest for both predictability and safety. Lee et al.33 
proposed that the remaining epithelial flap in LASEK acts as a smooth refractive 
surface and enables better initial visual acuity when LASEK is compared with PRK. 
When comparing visual outcomes between LASEK and Epi-LASIK, subclinical 
scarring or induced irregularity in Bowman's layer from superficial stromal cuts in 
Epi-LASIK may directly affect the visual quality.34 Comparisons of Epi-LASIK and 
T-PRK in relation to predictability are limited by a lack of data, and future trials may 
provide more solid evidence in this regard. 
Post-operative haze formation is an important factor that may directly influence the 
efficacy, safety and visual quality of corneal refractive surgery. Zhao et al.15 
contrasted LASEK and PRK in terms of corneal haze, reporting that LASEK-treated 
eyes showed less corneal haze at one month after surgery (WMD 0.25, 95% CI 
0.10-0.39) and three months after surgery (WMD 0.14, 95% CI 0.01-0.26) compared 
with PRK but no statistically significant difference was observed between the two 
groups at six months after surgery (WMD 0.14, 95% CI -0.02-0.30). In our results, 
there is also no statistical difference between LASEK and PRK at six months.  We 
found that Epi-LASIK and T-PRK performed best on SUCRA ranking in terms of 
haze. Epi-LASIK ranked best for any haze and also for haze scores greater than 1 
whereas T-PRK ranked best for haze scores greater than 0.5. This may be associated 
with the release of TGF-1. Baldwin et al.35 found cytokines and growth factors such 
as TGF-1 are released into the tear film by the lacrimal gland after corneal epithelial 
injury. Further, Long et al.36 found tear fluid TGF-1 levels were less following 
Epi-LASIK than after LASEK. TGF-1 levels correlated positively with the degree of 
haze, which was lower after Epi-LASIK compared to LASEK. 
Post-operative pain and epithelial healing time are two important factors that 
influence patient preference for a specific procedure. In 2002, Litwork et al.37 
reported that LASEK induced more pain than standard PRK. However in our study, 
the results showed that there was no statistically significant difference between PRK 
and LASEK, and SUCRA ranking showed that PRK was more likely to cause pain 
than LASEK 1 day post-operatively, which may be due to the exposure of sensitive 
nerve endings in the cornea following PRK, which is avoided in LASEK. It may also 
be the result of the release in chemical factors such as prostaglandin, histamine, and 
substance P by corneal tissue.38 Our study also found that Epi-LASIK showed more 
pronounced pain compared to PRK and T-PRK at day 3 post-operatively. 
In relation to epithelial healing time, our statistical results indicate that there is too 
high heterogeneity to draw reliable conclusions. Furthermore, post-operative topical 
drug regimes and the use of corneal contact lenses may influence post-operative 
epithelial healing time. In the present study, T-PRK achieves the highest ranking in 
terms of post-operative pain. This may be due to the precise, smooth, and regular 
epithelial ablation and lack of epithelial islands on the stromal bed.  
In terms of study limitations, like any traditional meta-analysis, the results are 
restricted by the differences between the included trials. These differences include: the 
race of study population, patient age, dioptric correction, choice of laser device 
including the year of manufacture and different post-operative medications. These 
factors may certainly have potential impacts on our results, but we found that the 
heterogeneity and inconsistency of studies to be low except in relation to epithelial 
healing time. Furthermore, the sensitivity analyses, whereby we removed studies with 
high heterogeneity or inconsistencies, this did not significantly alter the results. Also, 
these findings are only applicable to myopia as hyperopic treatments were not 
included and also studies using MMC were excluded. 
We chose six months post-surgery as the time point to analyze outcomes. This choice 
was driven by the availability of data from the various trials but does mean that we 
cannot evaluate the long-term stability of the outcomes. However, most long-term 
follow-up studies have shown that the operative results tend to stabilize by six 
months.39-41 Although a range of outcomes were assessed in this study, outcomes such 
as higher-order aberrations (HOAs), contrast sensitivity (CS) and patient reported 
outcomes such as subjective quality of vision (QoV) were not included due to a lack 
of data in the form of RCTs. This meta-analysis was also designed to compare 
techniques that differed in surgical design, rather than in relation to excimer laser 
ablation profile. 
In conclusion, this network meta-analysis demonstrates that all the surface laser 
refractive surgeries are comparable in efficacy, predictability safety, post-operative 
haze and comfort with the exception of pain score on day 3. Epi-LASIK was 
significantly more painful when compared with PRK and T-PRK 
on post-operative day 3.
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Figure 1: Study selection process  
  
Figure 2: Network of direct comparisons for corneal surface ablation surgeries for myopia. Each node represents 1 treatment. The size of the node is proportional to 




    
Epi-LASIK     
E: 0.75 (0.31, 1.75) 
P: 0.85 (0.37, 2.11) 
S: 0.90 (0.03, 49.55) 
LASEK   
E: 0.86 (0.36, 2.00) 
P: 1.03 (0.43, 2.51) 
S: 0.75 (0.01, 25.85) 
E: 1.16 (0.75, 1.79) 
P: 1.20 (0.77, 1.84) 
S: 0.77 (0.19, 2.95) 
PRK  
E: 1.27 (0.13, 12.86) 
P: NA 
S: 0.91 (0.01, 101.18) 
E: 1.62 (0.25, 13.72) 
P: NA 
S: 0.86 (0.03, 35.08) 
E: 1.43 (0.21, 12.46) 
P: NA 
S: 1.23 (0.04, 31.24) 
T-PRK 
Odds ratios (95% CrI) are calculated by column; E = Efficacy (UCVA of 20/20 or better); P = Predictability (Refractive SE 
within ±0.50 D of the target refraction); S = Safety (Losing two or more lines of BSCVA); NA = Not available. 
Figure 3: Summary comparison for postoperative efficacy, predictability and safety of all treatments derived from the network meta-analysis. 
 
    
Epi-LASIK     
HS: -0.08 (-0.62, 0.46) 
H0.5: 0.60 (0.16, 2.13) 
H1: 0.20 (0.02, 2.04) 
LASEK   
HS: -0.27 (-0.87, 0.33) 
H0.5: 0.67 (0.18, 2.25) 
H1: 0.27 (0.02, 2.57) 
HS: -0.19 (-0.46, 0.08) 
H0.5: 1.10 (0.58, 2.12) 
H1: 1.33 (0.40, 4.78) 
PRK  
HS: -0.09 (-0.86, 0.67) 
H0.5: 1.39 (0.22, 8.40) 
H1: 0.85 (0.03, 26.38) 
HS: -0.01 (-0.55, 0.52) 
H0.5: 2.26 (0.55, 9.89) 
H1: 4.31 (0.28, 75.55) 
HS: 0.17 (-0.42, 0.77) 
H0.5: 2.05 (0.59, 7.65) 
H1: 3.28 (0.26, 43.00) 
T-PRK 
Odds ratio (95% CrI) and mean difference (95% CrI) are calculated by column; HS = Haze scores; H0.5 = Haze grade 0.5 or 
higher; H1 = Haze grade 1.0 or higher.  
Figure 4: Summary comparisons for postoperative haze of all treatments derived from the network meta-analysis. 
 
    
Epi-LASIK     
PS1: 0.75 (-2.00, 3.41) 
PS3: 2.03 (-0.16, 4.03) 
EH: 0.09 (-0.76, 0.96) 
LASEK   
PS1: 0.06 (-2.43, 2.49) 
PS3: 2.17 (0.19, 4.01) 
EH: 0.08 (-0.81, 0.99) 
PS1: -0.69 (-1.79, 0.50) 
PS3: 0.12 (-0.69, 1.04) 
EH: -0.01 (-0.56, 0.56) 
PRK  
PS1: 0.54 (-2.34, 3.27) 
PS3: 2.69 (0.51, 4.84) 
EH: 1.65 (-0.21, 3.46) 
PS1: -0.20 (-1.69, 1.22) 
PS3: 0.64 (-0.39, 1.88) 
EH: 1.56 (-0.14, 3.23) 
PS1: 0.49 (-0.99, 1.82) 
PS3: 0.51 (-0.51, 1.67) 
EH: 1.57 (-0.04, 3.15) 
T-PRK 
Mean differences (95% CrI) are calculated by column; PS1 = pain scores on day 1; PS3 = pain scores on day 3; EH = 
epithelial healing time. The underlined data indicate a statistically significant effect (p < 0.05). 






















































Figure 6-8: Ranking plot of the surface ablation surgery network based on SUCRA values for 
post-operative efficacy (UCVA of 20/20 or better), predictability (refractive SE within ±0.50 D of 







Figure 9-11: Ranking plot of procedures based on SUCRA value for post-operative haze scores, 







Figure 12-14: Ranking plot of procedures based on SUCRA value for post-operative pain scores on 













Table 1 Names of treatment included in network meta-analyses 
Epi-LASIK = Epithelial laser in situ keratomileusis 
LASEK = Laser-assisted subepithelial keratectomy 
PRK = Photorefractive keratectomy 
T-PRK = Transepithelial photorefractive keratectomy 
 
Table 2 Post-operative efficacy, predictability and safety from direct comparisons between each pair of treatments 
 UCVA of 20/20 or better  
 
Refractive SE within ±0.50 D of the 
target 
 Losing two or more lines of BSCVA 
Number of 
Studies 
Odds Ratio  
(95% CI) 












PRK vs            
Epi-LASIK 2 1.23 (0.45, 3.34) 0.0%  2 0.87 (0.30, 2.47) 0.0%  1 1.00 (0.05, 17.90)   
LASEK 7 0.86 (0.58, 1.26) 0.0%  6 0.84 (0.58, 1.21) 0.0%  4 1.24 (0.32, 4.78) 0.0% 
T-PRK         1 1.00 (0.06, 16.51)  
LASEK vs            
Epi-LASIK 2 1.49 (0.62, 3.60) 0.0%  2 1.30 (0.47, 3.60) 0.0%     
T-PRK 1 1.56 (0.24, 10.05)       1 1.00 (0.06, 16.62)  
UCVA = uncorrected visual acuity; SE = spherical equivalent; BSCVA = best spectacle corrected visual acuity 
 
Table 3 Post-operative haze from direct comparisons between each pair of treatments 
 Haze Scores  
 
Haze grade 0.5 or higher  Haze grade 1.0 or higher 
Number 
of Studies 
















LASEK vs            
Epi-LASIK 1 0.08 (-0.02, 0.18)   1 1.00 (0.25, 4.00)   1 1.00 (0.06, 16.89)  
PRK 4 -0.19 (-0.37, -0.01) 88.9%  4 1.16 (0.71, 1.90) 0.0%  4 1.36 (0.57, 3.26) 0.0% 
T-PRK 1 -0.01 (-0.13, 0.11)          
PRK vs            
Epi-LASIK     1 2.80 (0.53, 14.74)   1 7.5 (0.73, 76.77)  
T-PRK     1 2.03 (0.83, 4.95)   1 2.70 (0.49, 14.79)  
The underlined data indicate that there is statistically significant effect (p < 0.05). 
 
 
Table 4 Post-operative pain scores and epithelial healing time from direct comparisons between each pair of treatments 




Mean difference  
(95% CI) 
I2  Number 
of 
Studies 












PRK vs             
Epi-LASIK 1 -0.01 (-1.76, 1.66)   1 -2.16 (-3.55, -0.77)   2 0.13 (-1.63, 1.90) 91.4  
LASEK 3 0.23 (-0.37, 0.83) 0.0%  3 -0.07 (-0.52, 0.38) 0.0%  8 0.04 (-0.54, 0.61) 97.1%  
T-PRK 1 1.24 (1.00, 1.48)   1 -0.48 (0.23, 0.73)   1 1.57 (1.39, 1.75)   
LASEK vs             
Epi-LASIK         3 -0.18 (-0.81, 0.46) 76.6%  
T-PRK 1 -1.23 (-2.10, -0.36)   1 0.87 (-0.39, 2.13)       









("Keratectomy, Subepithelial, Laser-Assisted"[Mesh] OR Laser-Assisted Subepithelial Keratectomy OR Laser Subepithelial Keratomileusis OR Laser-Assisted Sub
epithelial Keratomileusis  
OR LASEK OR epipolis laser in situ keratomileusis OR Epipolis laser in situ keratomileusis OR Epi-LASIK OR "Photorefractive Keratectomy"[Mesh] OR Photore
fractive Keratectomy  OR  
PRK OR TransPRK OR transepithelial PRK OR transepithelial photorefractive keratectomy OR 
refractive surgery OR laser surgery) AND (randomized controlled trial [pt] OR controlled clinical  
trial [pt] OR randomized [tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh])
 AND ((short OR near*) AND  
sight* OR myop* OR myopia[MeSH]) AND (pain [MeSH] OR pain* OR haze OR heal OR healing) 
--------------------------------------- 
Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Wiley) 
#1 MeSH descriptor: [Myopia] explode all trees  
#2 (short OR near*) next sight* 
#3 myop*  
#4 (#1 OR #2 OR #3) 
#5 MeSH descriptor: [Keratectomy, Subepithelial, Laser-Assisted] explode all trees 
#6 Laser-Assisted Subepithelial Keratectomy OR Laser Subepithelial Keratomileusis OR Laser-Assisted Subepithelial Keratomileusis OR LASEK 
#7 epipolis laser in situ keratomileusis OR Epipolis laser in situ keratomileusis OR Epi-LASIK  
#8 MeSH descriptor: [Photorefractive Keratectomy] explode all trees 
#9 Photorefractive Keratectomy OR PRK OR TransPRK OR transepithelial PRK OR transepithelial photorefractive keratectomy OR refractive surgery OR laser 
surgery 
#10 (#5 OR #6 OR #7 OR #8 OR #9) 
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#11 (#4 AND #10) 




#16 (#12 OR #13 OR #14 OR #15) 





3. (short or near*) near/3 sight* 
4. or/1-3 




9.'laser assisted' AND subepithelial AND keratectomy 
10.laser AND subepithelial AND keratomileusis 
11.'laser assisted' AND subepithelial AND keratomileusis 
12.lasek 
13.epipolis AND laser AND in AND situ AND keratomileusisor AND lasik 
14.epipolis AND laser AND in AND situ AND keratomileusis 
15.'epi lasik' 
16.photorefractive AND keratectomy 
17.prk 
18.'trans prk' 
19.refractive AND surgery 










28.4 AND 34 AND 35 
29. pain/exp 




34.28 AND 33 
--------------------------------------- 
ClinicalTrials.gov search strategy 










Treatment Number  
Of Eyes 
Mean Age 
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    0.32(0.25) 
0.16(0.23) 




















  4.18(0.58) 
4.86(0.64) 




















  0/25 
0/25 
     3.3(0.5) 
3.6(0.5) 






     0.31(0.14) 
0.23(0.08) 
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a Data of total; b Data from graph   
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High heterogeneity among some comparisons (Forest plots) 
LASEK vs PRK for postoperative Haze scores 
 
 


















Appendix 5  
Ranking probabilities 
Efficacy (UCVA of 20/20 or better) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.16 0.15 0.36 0.32 
LASEK 0.43 0.41 0.14 0.02 
PRK 0.14 0.36 0.38 0.12 
T-PRK 0.27 0.08 0.11 0.54 
 
Predictability (Refractive SE within ±0.50 D of the target) 
Drug Rank 1 Rank 2 Rank 3 
Epi-LASIK 0.34 0.2 0.46 
LASEK 0.54 0.36 0.1 
PRK 0.12 0.44 0.44 
 
Safety (Losing two or more lines of BSCVA)  
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.32 0.14 0.17 0.38 
LASEK 0.16 0.24 0.37 0.22 
PRK 0.19 0.45 0.29 0.08 
T-PRK 0.33 0.17 0.18 0.32 
 
 
Post-operative haze scores 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.12 0.17 0.21 0.51 
LASEK 0.02 0.32 0.49 0.17 
PRK 0.65 0.26 0.07 0.02 
T-PRK 0.22 0.25 0.23 0.3 
 
Postoperative haze grade 0.5 or higher 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.17 0.13 0.37 0.33 
LASEK 0.49 0.35 0.13 0.02 
PRK 0.27 0.46 0.25 0.02 





Postoperative Haze grade 1.0 or higher 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.05 0.07 0.36 0.52 
LASEK 0.61 0.27 0.10 0.01 
PRK 0.24 0.57 0.17 0.02 
T-PRK 0.10 0.08 0.37 0.45 
 
Post-operative pain scores on day 1 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.48 0.15 0.13 0.24 
LASEK 0.05 0.14 0.35 0.45 
PRK 0.34 0.48 0.15 0.03 
T-PRK 0.13 0.22 0.37 0.28 
 
Post-operative pain scores on day 3 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.96 0.02 0.01 0.01 
LASEK 0.02 0.62 0.3 0.05 
PRK 0.01 0.33 0.61 0.06 
T-PRK 0.01 0.04 0.08 0.88 
 
Post-operative pain scores on day 3 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.48 0.2 0.3 0.03 
LASEK 0.23 0.42 0.34 0.02 
PRK 0.27 0.38 0.34 0.01 






Node-splitting analysis of inconsistency 
Name Outcome Direct estimate (95% Cl) 






LASEK vs Epi-LASIK Efficacy 0.37 (-0.59, 1.30) 0.38 (-0.76, 1.60) 0.29 (-0.56, 1.16) 0.99 
Epi-LASIK vs PRK Efficacy -0.15 (-1.19, 0.68) 0.51 (-2.07, 2.49) -0.15 (-1.01, 0.69) 0.62 
LASEK vs PRK Efficacy 0.15 (-0.27, 0.60) -0.33 (-2.97, 2.17) 0.15 (-0.28, 0.58) 0.71 
LASEK vs Epi-LASIK Predictability 0.21 (-0.88, 1.27) -0.01 (-1.22, 1.20) 0.16 (-0.75, 0.98) 0.75 
Epi-LASIK vs PRK Predictability 0.05 (-0.92, 1.03) 0.24 (-2.74, 2.32) 0.03 (-0.84, 0.92) 0.86 
LASEK vs PRK Predictability 0.19 (-0.29, 0.61) 0.12 (-2.50, 2.58) 0.19 (-0.26, 0.61) 0.96 
LASEK vs Epi-LASIK 
Haze grade 
0.5 or higher -0.02 (-1.68, 1.75) 1.22 (-0.67, 3.34) 0.51 (-0.76, 1.83) 0.32 
Epi-LASIK vs PRK 
Haze grade 
0.5 or higher -1.04 (-3.07, 0.83) 0.17 (-1.66, 1.98) -0.40 (-1.73, 0.81) 0.34 
LASEK vs PRK 
Haze grade 
0.5 or higher 0.16 (-0.49, 0.85) -1.15 (-3.67, 1.36) 0.10 (-0.54, 0.75) 0.33 
LASEK vs Epi-LASIK 
Haze grade 
1.0 or higher -0.06 (-3.91, 3.74) 2.87 (-0.18, 7.00) 1.60 (-0.71, 4.13) 0.22 
Epi-LASIK vs PRK 
Haze grade 
1.0 or higher -2.31 (-6.26, 0.50) 0.50 (-3.48, 4.49) -1.29 (-3.76, 0.94) 0.23 
LASEK vs PRK 
Haze grade 
1.0 or higher 0.49 (-0.77, 1.82) -2.38 (-7.26, 2.62) 0.29 (-0.92, 1.57) 0.23 
LASEK vs PRK 
Pain scores 
on day 1 -0.22 (-1.27, 0.78) -2.44 (-4.51, -0.46) -0.69 (-1.79, 0.50) 0.05 
LASEK vs T-PRK 
Pain scores 
on day 1r -1.20 (-2.72, 0.29) 1.04 (-0.62, 2.65) -0.20 (-1.69, 1.22) 0.05 
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PRK vs T-PRK 
Pain scores 
on day 1 1.25 (-0.06, 2.56) -0.97 (-2.82, 0.81) 0.49 (-0.99, 1.82) 0.05 
LASEK vs PRK 
Pain scores 
on day 3 0.07 (-1.08, 1.39) 0.37 (-2.44, 3.14) 0.12 (-0.69, 1.04) 0.79 
LASEK vs T-PRK 
Pain scores 
on day 3 0.81 (-1.22, 3.00) 0.59 (-1.54, 2.84) 0.64 (-0.39, 1.88) 0.85 
PRK vs T-PRK 
Pain scores 
on day 3 0.49 (-1.27, 2.27) 0.82 (-1.71, 3.20) 0.51 (-0.51, 1.67) 0.74 
LASEK vs Epi-LASIK 
epithelial 
healing time -0.15 (-1.13, 0.90) 0.29 (-1.18, 1.64) -0.09 (-0.96, 0.76) 0.60 
Epi-LASIK vs PRK 
epithelial 
healing time -0.12 (-1.47, 1.24) 0.17 (-1.37, 1.58) 0.08 (-0.81, 0.99) 0.76 
LASEK vs PRK 
epithelial 





Removed trials that introduced high heterogeneity or statistical inconsistency across studies (outcome of post-operative haze scores in Autrata 2003 and 
outcome of pain scores on day 1 in Wang 2014) 
 
Comparison for postoperative haze scores of all treatments derived from 
network meta-analysis 
Epi-LASIK 0.08 (-0.14, 0.30) 0.18 (-0.08, 0.44) 0.09 (-0.22, 0.41) 
-0.08 (-0.30, 0.14) LASEK 0.10 (-0.03, 0.23) 0.01 (-0.22, 0.23) 
-0.18 (-0.44, 0.08) -0.10 (-0.23, 0.03) PRK -0.09 (-0.35, 0.17) 
-0.09 (-0.41, 0.22) -0.01 (-0.23, 0.22) 0.09 (-0.17, 0.35) T-PRK 
Mean difference (95% CrI) 
 
Ranking probabilities of postoperative haze scores 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.05 0.10 0.18 0.67 
LASEK 0.02 0.37 0.51 0.10 
PRK 0.73 0.21 0.04 0.01 
T-PRK 0.21 0.31 0.27 0.21 
 
SUCRA value of postoperative haze scores 









Comparison for postoperative pain scores on day 1 of all treatments derived 
from network meta-analysis 
Epi-LASIK -0.25 (-2.57, 2.01) -0.03 (-2.12, 2.03) -1.25 (-3.68, 1.12) 
0.25 (-2.01, 2.57) LASEK 0.23 (-0.78, 1.25) -0.99 (-2.62, 0.67) 
0.03 (-2.03, 2.12) -0.23 (-1.25, 0.78) PRK -1.23 (-2.54, 0.10) 
1.25 (-1.12, 3.68) 0.99 (-0.67, 2.62) 1.23 (-0.10, 2.54) T-PRK 
Mean difference (95% CrI) 
 
Ranking probabilities of post-operative pain scores on day 1 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.48 0.14 0.27 0.12 
LASEK 0.18 0.33 0.43 0.06 
PRK 0.33 0.50 0.16 0.01 
T-PRK 0.01 0.03 0.14 0.82 
 
SUCRA value of post-operative pain scores 
on day 1 
Treatment SUCRA value (%) 
Epi-LASIK 66.3 
LASEK 54.3 
PRK 71.7 
T-PRK 7.7 
 
